Released May 12, 2022, after the close
10-Q filed May 12, 2022, 42 days after period end · 0001390478-22-000012
Q1 2022 · 10-Q
Revenue$1.00M$1.00M −82.5% vs Q1 2021no prior Q4 2021 on file
Net Income-$16.74M-$16.74M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$1.05-$1.05 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$16,735,000N/M
Operating Cash Flow-$7,150,000N/M
Margins · derived
Operating margin-1673.5%−1634.1 pt vs Q1 2021
Net margin-1674.4%−1632.2 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $1.00M | $5.70M | $0.00 | — |
| Net Income | -$16.74M | -$2.40M | -$4.14M | -$4.54M |
| EPS Diluted | -$1.05 | -$0.16 | -$0.66 | -$11.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR